A
Andrew D. Skora
Researcher at Johns Hopkins University School of Medicine
Publications - 17
Citations - 11429
Andrew D. Skora is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Mutant & Phage display. The author has an hindex of 13, co-authored 17 publications receiving 8991 citations. Previous affiliations of Andrew D. Skora include Merck & Co. & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Brandon Luber,Nilofer S. Azad,Daniel A. Laheru,Barbara A. Biedrzycki,Ross C. Donehower,Atif Zaheer,George A. Fisher,Todd S. Crocenzi,James J. Lee,Steven M. Duffy,Richard M. Goldberg,Richard M. Goldberg,Albert de la Chapelle,Albert de la Chapelle,Minori Koshiji,Feriyl Bhaijee,Thomas Huebner,Ralph H. Hruban,Laura D. Wood,Nathan Cuka,Drew M. Pardoll,Nickolas Papadopoulos,Kenneth W. Kinzler,Shibin Zhou,Toby C. Cornish,Janis M. Taube,Robert A. Anders,James R. Eshleman,Bert Vogelstein,Luis A. Diaz +36 more
TL;DR: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab, and high somatic mutation loads were associated with prolonged progression-free survival.
Journal ArticleDOI
PD-1 blockade in tumors with mismatch repair deficiency.
Dung T. Le,Jennifer N. Uram,Hao Wang,Bjarne Bartlett,Holly Kemberling,Aleksandra Eyring,Andrew D. Skora,Nilofer S. Azad,Daniel A. Laheru,Ross C. Donehower,Brandon Luber,Todd S. Crocenzi,George A. Fisher,Steve M Duffy,James J. Lee,Minori Koshiji,James R. Eshleman,Robert A. Anders,Bert Vogelstein,Luis A. Diaz +19 more
TL;DR: MM status predicts clinical benefit of immune checkpoint blockade with pembrolizumab, and high total somatic mutation loads were associated with PFS.
Journal ArticleDOI
The Carnegie Protein Trap Library: A Versatile Tool for Drosophila Developmental Studies
Michael Buszczak,Shelley Paterno,Daniel V. Lighthouse,Julia L. Bachman,Jamie L. Planck,Stephenie Owen,Andrew D. Skora,Todd G. Nystul,Benjamin Ohlstein,Anna K. Allen,James E. Wilhelm,Terence D. Murphy,Robert W. Levis,Erika Matunis,Nahathai Srivali,Roger A. Hoskins,Allan C. Spradling,Allan C. Spradling +17 more
TL;DR: Using transposon mutagenesis in Drosophila, a library of 7404 protein trap and enhancer trap lines, the Carnegie collection, is constructed to facilitate gene expression mapping at single-cell resolution and finds that 600–900 different genes are trapped in the collection.
Journal ArticleDOI
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.
Kibem Kim,Andrew D. Skora,Zhaobo Li,Liu Qiang,Ada J. Tam,Richard L. Blosser,Luis A. Diaz,Nickolas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Shibin Zhou +10 more
TL;DR: It is reported that treatment with both anti–PD-1 and anti–CTLA-4 antibodies was unable to eradicate large, modestly immunogenic CT26 tumors or metastatic 4T1 tumors, and cancers resistant to immune checkpoint blockade can be cured by eliminating MDSCs.
Journal ArticleDOI
Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer
Christine G. Joseph,Erika Darrah,Ami A. Shah,Andrew D. Skora,Livia Casciola-Rosen,Fredrick M. Wigley,Francesco Boin,Andrea Fava,Christopher J. Thoburn,Isaac Kinde,Yuchen Jiao,Nickolas Papadopoulos,Kenneth W. Kinzler,Bert Vogelstein,Antony Rosen +14 more
TL;DR: Analysis of peripheral blood lymphocytes and serum suggested that POLR3A mutations triggered cellular immunity and cross-reactive humoral immune responses in patients with scleroderma and provided support for the idea that acquired immunity helps to control naturally occurring cancers.